Table 2.
VAHL characteristics following the third COVID-19 vaccine dose
| All VAHL cases | VAHL cases ≤ 5 days from vaccination | VAHL cases ≥ 6 days from vaccination | Pv | ||
|---|---|---|---|---|---|
| (n = 85) | (n = 47) | (n = 38) | |||
| Grading | Grade 1–2 VAHL | 69 (81%) | 31 (66%) | 38 (100%) | < 0.01* |
| Grade 3–4 VAHL | 16 (19%) | 16 (34%) | 0 (0%) | < 0.01* | |
| Intensity | SUVmax of the “hottest” node | 2.4 (1.7–3.5) | 3.4 (2.0–4.6) | 1.9 (1.5–2.6) | < 0.01* |
| Number | Number of “hot” nodes | 3 (2–5) | 4 (2–6) | 3 (2–4) | 0.03* |
| Number of “hot” nodes > 3 | 39 (46%) | 26 (55%) | 13 (34%) | 0.05* | |
| Location | Axilla – level 1 | 85 (100%) | 47 (100%) | 38 (100%) | > 0.99 |
| Axilla – level 2/3/interpectoral | 35 (41%) | 23 (49%) | 12 (32%) | 0.11 | |
| Supraclavicular | 7 (8%) | 7 (15%) | 0 (0%) | 0.02* | |
| Size | Enlarged lymph node | 11 (13%) | 7 (15%) | 4 (11%) | 0.75 |
| Injection site | Increased uptake | 56 (66%) | 42 (89%) | 14 (37%) | < 0.01* |
Pv refers to the comparison between the cases of VAHL observed ≤ 5 days from vaccination and the cases of VAHL observed ≥ 6 days from vaccination. Categorical variables are reported as frequency and percentage. Continuous variables are reported as median and IQR. VAHL, vaccine-associated hypermetabolic lymphadenopathy; SUVmax, maximum standardized uptake value